M.D. Sass LLC Has $63.26 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

M.D. Sass LLC grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 4.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 321,172 shares of the medical research company’s stock after purchasing an additional 12,227 shares during the quarter. Charles River Laboratories International comprises approximately 4.7% of M.D. Sass LLC’s investment portfolio, making the stock its 10th largest position. M.D. Sass LLC owned approximately 0.63% of Charles River Laboratories International worth $63,261,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Tortoise Investment Management LLC boosted its stake in Charles River Laboratories International by 77.0% during the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after acquiring an additional 57 shares in the last quarter. Wolff Wiese Magana LLC bought a new position in shares of Charles River Laboratories International during the 3rd quarter worth about $32,000. Assetmark Inc. grew its stake in shares of Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares during the period. Whittier Trust Co. of Nevada Inc. increased its position in Charles River Laboratories International by 219.3% in the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock valued at $58,000 after buying an additional 193 shares in the last quarter. Finally, Covestor Ltd raised its stake in Charles River Laboratories International by 40.9% during the 3rd quarter. Covestor Ltd now owns 327 shares of the medical research company’s stock worth $65,000 after buying an additional 95 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

CRL traded down $5.90 during trading hours on Tuesday, hitting $195.40. The stock had a trading volume of 46,802 shares, compared to its average volume of 622,342. Charles River Laboratories International, Inc. has a 1 year low of $176.48 and a 1 year high of $275.00. The company’s fifty day simple moving average is $194.94 and its 200 day simple moving average is $205.44. The stock has a market cap of $9.99 billion, a PE ratio of 25.18, a price-to-earnings-growth ratio of 5.05 and a beta of 1.38. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. During the same period in the prior year, the company posted $2.72 EPS. Charles River Laboratories International’s revenue was down 1.6% compared to the same quarter last year. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.19 earnings per share for the current year.

Charles River Laboratories International announced that its board has initiated a stock buyback program on Wednesday, August 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase up to 9.6% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Insider Transactions at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the sale, the director now directly owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Evercore ISI upped their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research note on Monday, November 18th. JPMorgan Chase & Co. lowered shares of Charles River Laboratories International from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $270.00 to $205.00 in a report on Thursday, August 8th. Citigroup cut Charles River Laboratories International from a “neutral” rating to a “sell” rating and cut their target price for the company from $215.00 to $175.00 in a research report on Tuesday, October 1st. Finally, UBS Group raised their price target on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Hold” and a consensus price target of $214.38.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).